Popular yogurt recalled; could contain sharp plastic pieces: FDA
Bread sold at Walmart and Kroger recalled
The recall alert states that Danone U.S. is voluntarily recalling all flavors and sizes of YoCrunch products currently inmarket and sold at retail stores nationwide.
According to the alert, consumers have reported the presence of plastic pieces in the toppers. Officials say the issue is isolated to the separately packaged topper and does not impact the separately packaged yogurt.
KFC offers free buckets of chicken in 'comeback'
'The plastic pieces are transparent, may have sharp edges, and could present a risk to consumers because some pieces are between 7 and 25 mm in length,' reads the alert. 'The company is working swiftly with retail partners to remove the impacted product from shelves, while it works to address the issue and bring back the YoCrunch® products so many people enjoy.'
Impacted product names and code dates are below (provided by the FDA):
Product
LOT #/EXP DATE
YOCRUNCH STRAW W/GRANOLA 6OZ(UPC 46675000105)
2025.07.07, 2025.07.12, 2025.07.26, 2025.08.03, 2025.08.08, 2025.08.19,2025.08.22, 2025.08.30, 2025.09.04
YOCRUNCH VANILLA W/M&M 6OZ(UPC 46675000792)
2025.07.11, 2025.07.14, 2025.07.25, 2025.08.07, 2025.08.11, 2025.08.22, 2025.08.26, 2025.09.03
YOCRUNCH VANILLA W/OREO 6OZ (UPC 46675000808)
2025.07.11, 2025.07.14, 2025.07.24, 2025.07.25 2025.08.06, 2025.08.11, 2025.08.21, 2025.08.26, 2025.09.03
YOCRUNCH STRAW W/M&M 6OZ (UPC 46675000839)
2025.07.12, 2025.07.25, 2025.08.07, 2025.08.22, 2025.09.04
YOCRUNCH VANILLA W/SNICKERS 6OZ (UPC 46675001126)
2025.07.10, 2025.07.24, 2025.08.06, 2025.08.21
YOCRUNCH VANILLA W/TWIX CANDY 6OZ (UPC 46675001133)
2025.07.24, 2025.08.07, 2025.08.21
YOCRUNCH STRAW W/M&M MULTI 4X4OZ (UPC 46675013129)
2025.07.08, 2025.07.12, 2025.07.13, 2025.07.17, 2025.07.18, 2025.07.26, 2025.07.27, 2025.08.02, 2025.08.03, 2025.08.09, 2025.08.11, 2025.08.12, 2025.08.13, 2025.08.15, 2025.08.16, 2025.08.23, 2025.08.24, 2025.08.29, 2025.08.30, 2025.08.31
YOCRUNCH VAN W/COOKIE DOUGH 4X4OZ (UPC 46675013150)
2025.07.17, 2025.08.01, 2025.08.13, 2025.08.29
YOCRUNCH VANI W/SNICKER PCS 4X4OZ (UPC 46675013266)
2025.07.17, 2025.08.01, 2025.08.13, 2025.09.01
YOCRUNCH VANI W/TWIX CANDY 4X4OZ (UPC 46675013273)
2025.07.17, 2025.08.01, 2025.08.14, 2025.08.29
YOCRUNCH VANILLA OREO 4X4OZ(UPC 46675013501)
2025.07.13, 2025.07.14, 2025.07.20, 2025.07.21, 2025.07.24, 2025.07.25, 2025.07.26, 2025.07.31, 2025.08.01, 2025.08.02, 2025.08.08, 2025.08.09, 2025.08.10, 2025.08.11, 2025.08.15, 2025.08.16, 2025.08.23, 2025.08.24, 2025.08.25, 2025.08.30, 2025.08.31
YOCRUNCH VANILLA M&M 4X4OZ (UPC 46675013518)
2025.07.07, 2025.07.09, 2025.07.14, 2025.07.15, 2025.07.16, 2025.07.17, 2025.07.22, 2025.07.23, 2025.07.26, 2025.07.27, 2025.07.28, 2025.08.02, 2025.08.03, 2025.08.05, 2025.08.06, 2025.08.07, 2025.08.10, 2025.08.13, 2025.08.14, 2025.08.16, 2025.08.17,2025.08.18, 2025.08.19, 2025.08.20, 2025.08.21, 2025.08.22, 2025.08.26, 2025.08.27, 2025.08.28, 2025.08.29, 2025.09.01, 2025.09.02, 2025.09.03, 2025.09.04
YOCRUNCH VAN OREO & M&M FR PK 8X6OZ(UPC 46675014003)
2025.07.12, 2025.07.13, 2025.07.14, 2025.07.15, 2025.07.16, 2025.07.20, 2025.07.21, 2025.07.22, 2025.07.23, 2025.07.24, 2025.07.25, 2025.07.28, 2025.08.02, 2025.08.03, 2025.08.04, 2025.08.05, 2025.08.06, 2025.08.07, 2025.08.10, 2025.08.11, 2025.08.12, 2025.08.13, 2025.08.14, 2025.08.17,2025.08.18, 2025.08.19, 2025.08.20, 2025.08.21, 2025.08.22, 2025.08.23, 2025.08.25, 2025.08.26, 2025.08.27, 2025.08.28, 2025.08.29, 2025.09.02
YOCRUNCH STR/RAS GRNLA FR PK 8X6OZ (UPC 46675014010)
2025.07.26, 2025.08.23, 2025.08.30
YOCRUNCH STRW W/M&M&OREO FR PK 8X6OZ (UPC 46675026136)
2025.07.22, 2025.08.03, 2025.08.19, 2025.08.29
YOCRUNCH VAN W/SNIC&TWIX FR PK 8X6OZ (UPC 46675026143)
2025.07.14, 2025.07.28, 2025.08.11, 2025.08.26
YOCRUNCH VAN OREO/VAN M&M 18X6OZ CLB (UPC 46675027010)
2025.07.11, 2025.07.19, 2025.07.20,2025.07.26, 2025.07.27, 2025.07.28, 2025.07.31, 2025.08.01, 2025.08.02, 2025.08.08, 2025.08.09, 2025.08.16, 2025.08.17, 2025.08.23, 2025.08.24, 2025.08.25, 2025.08.30, 2025.08.31
Consumers who have purchased the affected products are advised not to consume them.
'Danone U.S., the makers of YoCrunch, takes every consumer experience seriously and is initiating this voluntary recall in line with its commitment to product quality and consumer safety,' reads the recall alert.
For information on refunds, contact the YoCrunch Consumer Care Line at 1-877-344-4886.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
38 minutes ago
- New York Post
Boomers are sitting on nearly $19 trillion in real estate — here's where they hold the most housing health
Advertisement Baby boomers are sitting on a staggering amount of housing wealth—across the U.S., they own an estimated $18 trillion to $19 trillion worth of real estate. Boomers now hold nearly half of the nation's real estate wealth. This is a direct reflection of decades of homeownership, rising property values, and the generational shift that is now reshaping the housing market. But, where exactly is that wealth concentrated? A new analysis reveals that while boomers—those born between 1946 and 1964—have planted roots across the country, a handful of metro areas stand out as hotbeds for retiree real estate wealth. Unsurprisingly, Florida dominates the list, claiming five of the top 10 spots. Advertisement 7 Baby Boomers own an estimated $18 trillion to $19 trillion worth of real estate. 7 Boomers now hold nearly half of the nation's real estate wealth. Syda Productions – The Sunshine State offers warm weather, no state income tax, and a lifestyle that's long appealed to retirees—but other destinations, from coastal California to scenic New England, are also popular. The ranking combines three factors: the share of homeowners aged 65 and up, the total value of homes in each market, and the estimated value held by older residents. The result is a snapshot of where retirees aren't just living—but where they're holding some of the most valuable pieces of the American housing pie. Advertisement The wealthiest retiree markets in America North Port-Bradenton, FL Real estate value held by homeowners aged 65 and up: $97 billion Share of homeowners aged 65 and up: 56% Median home price: $495,000 In this metro, located in Sarasota and Manatee counties on the coast, more than half of homeowners are boomers. North Port isn't strictly a beach town; the metro includes miles of coastline and many other popular destinations such as Venice Beach. This means retirees have options: either direct access to the beach, or proximate access without having to pay some of the steeper prices that come with the territory. They also own an estimated $97 billion of the roughly $174 billion real estate value in this metro. 7 The Sunshine State offers warm weather, no state income tax, and a lifestyle that's long appealed to retirees. Vane Nunes – Advertisement 7 The ranking combines three factors: the share of homeowners aged 65 and up, the total value of homes in each market, and the estimated value held by older residents. Naples-Marco Island, FL Real estate value held by homeowners aged 65 and up: $70 billion Share of homeowners aged 65 and up: 57% Median home price: $749,000 Also located on Florida's west coast, this area is known as the Sunshine State's Paradise Coast. It offers white-sand beaches, luxury resorts, and an abundance of outdoor activities, with more than 90 golf courses. With more homes within proximity to the water, the area has a higher price range, with the median list price of $749,000. The 65 and older age group owns about $70 billion out of the $122 billion real estate value in Naples-Marco Island. Santa Rosa-Petaluma, CA Real estate value held by homeowners aged 65 and up: $54 billion Share of homeowners aged 65 and up: 47% Median home price: $995,000 Located roughly 40 miles north of San Francisco, this area is in Sonoma County, famed for its wine country and access to nature for active retirees. 'Santa Rosa as a whole is geared toward retirees,' Fermin Escutia, real estate agent at W Real Estate, tells 'Petaluma is the most affordable town north of San Francisco. The sizes of the homes are going to be smaller, but the draw is the small community feel with plenty of events.' Advertisement 7 Map of the U.S. showing top 10 metro areas where retirees hold the most real estate wealth. 7 Located roughly 40 miles north of San Francisco, this area is in Sonoma County, famed for its wine country and access to nature for active retirees. The scenic foggy metro comes at a cost, with a median list price of $995,000. Of the homeowners here, 47% are those aged 65 and up, and they hold roughly $54 billion of the $116 billion real estate value. Barnstable Town, MA (Cape Cod) Real estate value held by homeowners aged 65 and up: $34 billion Share of homeowners aged 65 and up: 53% Median home price: $899,250 Advertisement The Cape Cod region has been a favorite destination among retirees for years, and many are drawn here by the coastal charm despite the chilly New England weather, as well as a slower pace outside the Boston area. 'The summers are beautiful here, and Barnstable has little hidden gems and local villages and charm you can't discover in just one weekend,' Deborah Garner, a real estate agent with Kinlin Grover Compass, tells 7 Of the homeowners here, 47% are those aged 65 and up, and they hold roughly $54 billion of the $116 billion real estate value. But soaking up this classic charm full time comes at a cost, with a median list price of $899,250. New listings are down 6.5% from a year ago, and new construction in the Northeast is less active than in some Southern and Midwestern states, resulting in fewer options available. Homeowners aged 65 and up accounted for $34 billion out of the $64 billion real estate value. 'There is a generational effect where property gets passed down and families find it hard to part with homes,' says Garner. Advertisement Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here! Prescott-Prescott Valley, AZ Real estate value held by homeowners aged 65 and up: $27 billion Share of homeowners aged 65 and up: 58% Median home price: $669,000 In Arizona's Prescott-Prescott Valley market, those aged 65 and up own 58% of the homes. The Prescott area is known for its older demographic, with a median age of 60.3, while the Prescott Valley area tends to draw a younger crowd, according to U.S. Census Bureau data. Arizona, as a state, is a popular destination for retirees, and Prescott-Prescott Valley offers a warm climate without the humidity found in Florida. Insurance costs are lower, too, due to the lack of hurricane threats. The median list price for the area comes in at $669,000, with those aged 65 and up owning $27 billion of the $47 billion real estate value.
Business Wire
an hour ago
- Business Wire
American Airlines and Mastercard Renew Partnership for Even More Rewarding Travel Experiences
FORT WORTH, Texas & PURCHASE, N.Y.--(BUSINESS WIRE)--American Airlines and Mastercard today announced an extension of their decades-long partnership, reinforcing a shared commitment to delivering more rewarding travel experiences and value through advanced payments technology and services. 'American is proud to collaborate with Mastercard to deliver best-in-class travel solutions for our AAdvantage® co-branded credit cardmembers,' said American's CEO Robert Isom. 'American is proud to collaborate with Mastercard to deliver best-in-class travel solutions for our AAdvantage ® co-branded credit cardmembers,' said American's CEO Robert Isom. 'Together, we are rewarding our mutual customers with travel experiences that make their journeys truly special.' The agreement secures Mastercard as the exclusive payment network partner for American's co-branded credit cards, building on nearly 40 years of collaboration between the two companies. Together, American and Mastercard will continue to enhance the AAdvantage ® program — American's industry-leading travel rewards program — while providing cardholders with seamless and personalized experiences on every trip. 'We're incredibly proud of our partnership with American Airlines and the nearly 40 years of priceless experiences, benefits and innovation the program has brought to cardholders,' said Michael Miebach, CEO at Mastercard. 'Looking to the future, we'll continue to bring our expanded suite of products and services to deliver what cardmembers want: personalized offers, valuable rewards, fraud protection and opportunities to explore their passions.' Enhancing the customer experience American will enhance its AAdvantage ® program using Mastercard's payments infrastructure and analytics to deliver more personalized offers, optimized rewards and seamless, secure transactions. Mastercard's technology will power real-time fraud detection and optimize payments from booking to in flight. Advanced analytics will help refine the customer travel experience while AAdvantage ® members gain new ways to redeem miles for Mastercard Priceless Experiences. Unlocking priceless possibilities for cardholders A hallmark of the American and Mastercard partnership is the ability to bring cardmembers closer to the experiences they value most. From upgraded travel privileges to once-in-a-lifetime Priceless Experiences — such as meet-and-greets with world-class athletes, VIP access at major cultural events and behind-the-scenes tours at iconic destinations — cardholders enjoy curated access designed to surprise and delight. As American and Mastercard look to the future, they remain committed to delivering innovative, personalized offerings that meet the needs of today's global traveler, ensuring every trip is not only seamless, but priceless. About American Airlines As a leading global airline, American Airlines offers thousands of flights per day to more than 350 destinations in more than 60 countries. The airline is a founding member of the oneworld alliance, whose members serve more than 900 destinations around the globe. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL. Learn more about what's happening at American by visiting and connect with American @AmericanAir and at To Care for People on Life's Journey ®. About Mastercard Mastercard powers economies and empowers people in 200+ countries and territories worldwide. Together with our customers, we're building a resilient economy where everyone can prosper. We support a wide range of digital payments choices, making transactions secure, simple, smart and accessible. Our technology and innovation, partnerships and networks combine to deliver a unique set of products and services that help people, businesses and governments realize their greatest potential.
Yahoo
5 hours ago
- Yahoo
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys
The ground shook for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) last week as the U.S. Food and Drug Administration (FDA), alarmed by a third patient death tied to its gene therapy platform, pulled a rare move: requesting a voluntary halt to Elevidys shipments. The company's response? A resounding 'no,' igniting a major regulatory clash with severe implications for patients and investors alike. The upheaval began on Friday when the U.S. Food and Drug Administration (FDA) made a rare and impactful announcement: it had placed Sarepta's investigational gene therapy clinical trials for limb girdle muscular dystrophy (LGMD) on a clinical hold. This decision stemmed from serious safety concerns, including three patient deaths potentially linked to these products, indicating that study participants faced or would be exposed to an unreasonable and significant risk of illness or injury. In light of these developments, the FDA also formally requested Sarepta to voluntarily halt all shipments of Elevidys, the company's approved gene therapy. However, in a move that set the stage for a major regulatory clash with severe implications for both patients and investors, Sarepta definitively refused this three fatalities, which prompted the FDA's strong action, have resulted from acute liver failure in individuals who had received either Elevidys or an investigational gene therapy utilizing the same AAVrh74 serotype, a viral vector used in gene delivery. Notably, one of these deaths occurred during a clinical trial for LGMD, conducted under an investigational new drug application. Adding to Sarepta's challenges, the FDA further revoked the platform technology designation for the company's AAVrh74 Platform Technology. This designation, typically granted to technologies with broad therapeutic promise that can streamline regulatory review, was rescinded because, given the new safety information, the preliminary evidence was deemed insufficient to demonstrate that the AAVrh74 Platform Technology could be incorporated into or utilized by multiple drugs without adverse effects on safety. Elevidys had received traditional approval in June 2024 for ambulatory Duchenne muscular dystrophy (DMD) patients aged four years and older with a confirmed DMD gene mutation. Previously, in June 2023, it secured accelerated, conditional approval for non-ambulatory DMD patients. However, continued approval for non-ambulatory patients is contingent upon verification of clinical benefit through confirmatory trials. With the emergence of this new safety data, the FDA notified Sarepta that Elevidys's indication should now be restricted solely to ambulatory patients. The FDA is continuing its investigation into the risk of acute liver failure, including severe outcomes such as hospitalization and death, associated with gene therapies employing Sarepta's AAVrh74 Platform Technology, and is prepared to take further regulatory actions as necessary. Despite the FDA's stance, Sarepta issued a statement on Friday affirming its decision to continue shipping Elevidys to the ambulatory patient population. The company asserted that its 'comprehensive scientific interpretation of the data... shows no new or changed safety signals in the ambulant patient population.' Sarepta also expressed its commitment to ongoing discussions and information sharing with the FDA to advance their 'shared purpose of protecting patient safety and informed access to care.' The company clarified that the most recent fatal event occurred in a Phase 1 clinical trial for an investigational gene therapy called SRP-9004, which is designed to treat a different condition, LGMD Type 2D. Sarepta emphasized that SRP-9004 is administered at a different dose and manufactured using a distinct process from Elevidys. Furthermore, the LGMD study participant who passed away was not treated with Elevidys, and dosing for the SRP-9004 trial had already concluded at the time of death. Sarepta reported this acute liver failure (ALF) event as a life-threatening case to the FDA on June 20 and subsequently notified the agency of the death on July 3. Looking ahead, Sarepta plans to submit the findings of an expert panel and a proposed protocol to the FDA. They will also discuss a proposal to collect additional data on a modified treatment regimen in a new cohort (Cohort 8) of the ENDEAVOR study (Study SRP-9001-103). This is intended as a pathway to re-establish dosing for non-ambulant patients in the future. Price Action: As of Monday's premarket session, Sarepta's stock was down 6.79% at $13.12, reflecting the ongoing concerns and market reaction to these significant developments. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? SAREPTA THERAPEUTICS (SRPT): Free Stock Analysis Report This article Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
